Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TYK MedicinesHKSE:02410 -4.51%7 3-Year ROIIC % is 8.57 as of Dec. 2025, which is at its 10-year median of 8.57. GuruFocus rates HKSE:02410 with a GF Score™ of 7/100. The stock has 3 warning signs investors should review. Among 1,316 Biotechnology companies, TYK Medicines ranks better than 60.33% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
TYK Medicines's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 8.57%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for TYK Medicines's 3-Year ROIIC % or its related term are showing as below:
HKSE:02410's 3-Year ROIIC % is ranked better than 60.33% of 1316
companies
in the Biotechnology industry
Industry Median: -4.42
vs HKSE:02410: 8.57
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
TYK Medicines 3-Year ROIIC % Related Terms
TYK Medicines 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for TYK Medicines's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:02410 vs VRTX, REGN, RVMD: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, TYK Medicines's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TYK Medicines 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, TYK Medicines's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where TYK Medicines's 3-Year ROIIC % falls into.
TYK Medicines's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -326.231 (Dec. 2025) - -262.198 (Dec. 2022) )
/
( 599.625 (Dec. 2025) - 1346.767 (Dec. 2022) )
=
-64.033
/
-747.142
=
8.57%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
TYK Medicines (HKSE:02410) has a 3-Year ROIIC % of 8.57 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on TYK Medicines and its competitors. This is near median its historical median of 8.57. Over the past decade, TYK Medicines' 3-Year ROIIC % has ranged from 8.57 to 8.57. According to the industry distribution chart, TYK Medicines ranks #522 out of 1316 companies in the Biotechnology industry, placing it in the top 39.7%.
Is TYK Medicines' 3-Year ROIIC % too high?
TYK Medicines' current 3-Year ROIIC % of 8.57 is near median its 10-year median of 8.57. Over the past 10 years, this metric has ranged from a low of 8.57 to a high of 8.57. Based on the distribution chart, TYK Medicines ranks #522 out of 1316 companies in the Biotechnology industry, which is above the industry midpoint. Overall, TYK Medicines has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does TYK Medicines' 3-Year ROIIC % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, TYK Medicines ranks #522 out of 1316 companies for 3-Year ROIIC %. This puts TYK Medicines in the upper half of its industry. Historically, TYK Medicines' own 3-Year ROIIC % has ranged from 8.57 to 8.57 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on TYK Medicines and its competitors. TYK Medicines's current 3-Year ROIIC % is 8.57, which is near median its own 10-year median of 8.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TYK Medicines stock overvalued right now?
TYK Medicines (HKSE:02410) has a current 3-Year ROIIC % of 8.57. The current 3-Year ROIIC % is 8.57, which is near median its 10-year median of 8.57. TYK Medicines' overall GF Score™ is 7/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For TYK Medicines (HKSE:02410), the current 3-Year ROIIC % is 8.57 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
TYK Medicines Inc is a clinical-stage biopharmaceutical company. The company is engaged in drug discovery research and development. The company and its subsidiaries are principally engaged in the research, development, and commercialization of pharmaceutical products. The company has built a pipeline with10 drug candidates, including Core Product TY-9591, five clinical stage products, and four preclinical stage or early clinical development stage.
7GF Score
Get the complete analysis for HKSE:02410
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02410 has been successfully added to your 
